Abstract:The gut-liver axis covers the bidirectional communication between the gut and the liver, and thus includes signals from liver-to-gut (e.g., bile acids, immunoglobulins) and from gut-to-liver (e.g., nutrients, microbiota-derived products, and recirculating bile acids). In a healthy individual, liver homeostasis is tightly controlled by the mostly tolerogenic liver resident macrophages, the Kupffer cells, capturing the gut-derived antigens from the blood circulation. However, disturbances of the gut-liver axis have been associated to the progression of varying chronic liver diseases, such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and primary sclerosing cholangitis. Notably, changes of the gut microbiome, or intestinal dysbiosis, combined with increased intestinal permeability, leads to the translocation of gut-derived bacteria or their metabolites into the portal vein. In the context of concomitant or subsequent liver inflammation, the liver is then infiltrated by responsive immune cells (e.g., monocytes, neutrophils, lymphoid, or dendritic cells), and microbiota-derived products may provoke or exacerbate innate immune responses, hence perpetuating liver inflammation and fibrosis, and potentiating the risks of developing cirrhosis. Similarly, food derived antigens, bile acids, danger-, and pathogen-associated molecular patterns are able to reshape the liver immune microenvironment. Immune cell intracellular signaling components, such as inflammasome activation, toll-like receptor or nucleotide-binding oligomerization domain-like receptors signaling, are potent targets of interest for the modulation of the immune response. This review describes the current understanding of the cellular landscape and molecular pathways involved in the gut-liver axis and implicated in chronic liver disease progression. We also provide an overview of innovative therapeutic approaches and current clinical trials aiming at targeting the gut-liver axis for the treatment of patients with chronic liver and/or intestinal diseases.

Role of the Intestinal Microbiome in Liver Fibrosis Development and New Treatment Strategies

The Gut Microbiome and Intestinal Failure-Associated Liver Disease

Disorganized Gut Microbiome Contributed to Liver Cirrhosis Progression: A Meta-Omics-Based Study

Role of Intestinal Microbes in Chronic Liver Diseases

Liver cirrhosis: molecular mechanisms and therapeutic interventions

Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives

Nonalcoholic Fatty Liver Disease and the Intestinal Microbiome: An Inseparable Link

Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis

Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations

The gut microbiota–bile acid axis: A potential therapeutic target for liver fibrosis

Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases

The Gut Microbiome and Gut-Liver Axis in NAFLD

Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases

Intestinal Fibrosis and Gut Microbiota: Clues From Other Organs

Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases

Gut Microbiome, Liver Immunology, and Liver Diseases

The role of the microbiome in liver disease

Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut–liver axis

Potential mechanisms of traditional Chinese medicine in the treatment of liver cirrhosis: a focus on gut microbiota

Interactions between gut microbiota and non-alcoholic liver disease: The role of microbiota-derived metabolites

The Role of Gut Bacteria and Fungi in Alcohol-Associated Liver Disease